Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Want to see SLNO full AI Analyst Report?
Total Valuation
Soleno Therapeutics has a market cap or net worth of $2.76B. The enterprise value is $2.63B.
Market Cap$2.76B
Enterprise Value$2.63B
Share Statistics
Soleno Therapeutics has 52,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,120,148
Owned by Insiders2.00%
Owned by Institutions45.45%
Financial Efficiency
Soleno Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 2.97%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)2.97%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee1.66M
Profits Per Employee181.65K
Employee Count115
Asset Turnover0.34
Inventory Turnover0.18
Valuation Ratios
The current PE Ratio of Soleno Therapeutics is 13.9. Soleno Therapeutics’s PEG ratio is -1.08.
PE Ratio13.9
PS Ratio12.93
PB Ratio5.47
Price to Fair Value5.47
Price to FCF52.69
Price to Operating Cash Flow26.12
PEG Ratio-1.08
Income Statement
In the last 12 months, Soleno Therapeutics had revenue of 190.41M and earned 20.89M in profits. Earnings per share was 0.41.
Revenue190.41M
Gross Profit187.71M
Operating Income14.95M
Pretax Income20.89M
Net Income20.89M
EBITDA28.38M
Earnings Per Share (EPS)0.41
Cash Flow
In the last 12 months, operating cash flow was 105.71M and capital expenditures -108.00K, giving a free cash flow of 105.60M billion.
Operating Cash Flow105.71M
Free Cash Flow105.60M
Free Cash Flow per Share2.03
Dividends & Yields
Soleno Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change-29.86%
50-Day Moving Average40.07
200-Day Moving Average55.82
Relative Strength Index (RSI)77.93
Average Volume (3m)5.18M
Important Dates
Soleno Therapeutics upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Soleno Therapeutics as a current ratio of 5.80, with Debt / Equity ratio of 0.89%
Current Ratio5.80
Quick Ratio5.55
Debt to Market Cap<0.01
Net Debt to EBITDA-2.38
Interest Coverage Ratio2.73
Taxes
In the past 12 months, Soleno Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Soleno Therapeutics EV to EBITDA ratio is 84.37, with an EV/FCF ratio of 51.25.
EV to Sales12.58
EV to EBITDA84.37
EV to Free Cash Flow51.25
EV to Operating Cash Flow51.17
Balance Sheet
Soleno Therapeutics has $255.60M in cash and marketable securities with $4.41M in debt, giving a net cash position of $251.19M billion.
Cash & Marketable Securities$255.60M
Total Debt$4.41M
Net Cash$251.19M
Net Cash Per Share$4.82
Tangible Book Value Per Share$8.37
Margins
Gross margin is 98.63%, with operating margin of 7.85%, and net profit margin of 10.97%.
Gross Margin98.63%
Operating Margin7.85%
Pretax Margin10.97%
Net Profit Margin10.97%
EBITDA Margin14.91%
EBIT Margin13.85%
Analyst Forecast
The average price target for Soleno Therapeutics is $61.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$61.00
Price Target Upside15.57% Upside
Analyst ConsensusHold
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast―